Activity Expired

2008 Psychopharmacology Update – Online CME Program

2008 Psychopharmacology Update – Online CME Program
Successful Transition from Acute to Maintenance Psychopharmacological Treatments in Child and Adolescent Psychiatry Sponsored by eAACAP, Chaired by Robert Hendren, D.O.
Supported through an educational grant from Eli Lilly and Company.

PROGRAM GOALS AND OVERVIEW
The goal of the 2008 Psychopharmacology Update Online Program is to provide an update regarding the similarity and differences between acute and maintenance use of psychotropic medication treatments for psychiatric disorders in children, adolescents, and adults. Practitioners are exposed to expert opinions and the most current data on optimal use of medication treatments for both intense, severe, and acute symptoms of psychiatric disorders in children and adolescents, as well as the optimal management of those medications to reduce long-term impairment from the disorders.

Learning Objectives
At the conclusion of this online CME activity, the participant should be able to:

1. Identify the guidelines for both acute and long term treatment of Tourette’s and tic disorders, and discuss the impact and treatment of psychiatric comorbid disorders.
2. Explain rational medication treatment options for acute treatment of youth with major depressive disorder.
3. Name the medications that have been approved by the FDA for treatment of acute mania in adults, adolescents, and children, and ways in which the differential diagnosis of mania is relevant to which medications used.
4. Describe the degree of effectiveness in controlled studies of medications used to treat children and adolescents with ADHD, and identify the short-coming in our understanding of relapse prevention.
5. Discuss the common endocrine complications of current psychopharmacological agents and how their manifestations and management vary during short and long term drug administration.
6. Define various anxiety disorders and discuss the pharmacological treatments available for childhood anxiety disorders.
7. Identify the three most common classes of medications used in the treatment of pervasive development disorders (PDDs) and the long-term effects of such medications.

Target Audience
This educational activity is designed for child and adolescent psychiatrists, pediatricians, family practice physicians, and other healthcare professionals with a special interest in the psychopharmacological treatment of children and adolescents.

Original Release Date: April 30, 2008
Review Date: April 28, 2008
Expiration Date: April 30, 2009

Faculty
Gabrielle A. Carlson, M.D.
Professor of Psychiatry and Pediatrics
Director, Child and Adolescent Psychiatry
Stony Brook University School of Medicine
Stony Brook, NY

Harold E. Carlson, M.D.
Professor of Medicine
Division Head, Endocrinology
Stony Brook University
Stony Brook, NY

Barbara J. Coffey, M.D., M.S.
Associate Professor, Department of Child and Adolescent Psychiatry
NYU Child Study Center
Director, Institute for Tourette and Tic Disorders
New York University School of Medicine
New York, NY

Graham J. Emslie, M.D.
Professor of Psychiatry
Division Chief, Child and Adolescent Psychiatry
University of Texas Southwestern Medical Center
Dallas, TX

Laurence L. Greenhill, M.D., Chair
Ruane